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ABS'mACT 
Lymphocyte cultures grown from liver allograft biopsies 
were shown to exhibit alloreactivity towards donor cells as 
measured by primed lymphocyte testing (PLT). The PLT 
s p e c i f i cit Y was de t e r min e din ass a y sus i n g HLA t Y P e d pan e I 
cells and/or by inhibition testing with ULA specific 
monoclonal antibodies. Certain cultures exhibited PLT 
specificity towards class I HLA antigens of the donor, 
whereas others were specific for class II HLA antigens or 
r e cog n i zed mix t u res 0 f c I ass I and I I ant i g ens. Th e s e P L T 
specificity patterns were compared " wi th cl inical, 
histological and laboratory findings on the liver transplant 
patients at the time of the biopsy. Biopsies yielding class 
I specific PLT cells were taken generally during the earlier 
posttransplant period, whereas class II specific cells were 
grown from 1 ate r b i 0 psi e s • Th ere was nos i g n i f i can t 
correlation of the PLT specificity towards class I vs II 
antigens with the levels of total or direct bilirubin, serum 
glutamate oxaloacetic transaminase (SOOT) , and serum 
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glutamate pyruvate transaminase (SGPT), al though a trend 
towards higher values was noted for biopsies presenting with 
a class II specific infiltrate. However, the levels of gamma 
glutamyl transpept idase (GGTP) and alkal ine phosphatase (AP) 
were significantly increased when biopsies yielded class II 
specific rather than class I specific PLT cells. Biopsy 
histology showed more damage to bile duct epithelium in 
association with class II PLT specificity whereas intense 
but often reversible infiltrates were found in biopsies 
yielding class I specific cells. The elevated GGTP and AP 
levels are probably related to the interaction of class II 
s p e c i f i c T c ell s wit h b i 1 e d u c t e pit he I i urn, w h i c h has bee n 
shown to express induced class II HLA antigens on their cell 
surface. 
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fkmoarCqf~ 
While liver transplantation has become an accepted form 
of treatment for a variety of endstage liver diseases, the 
understanding of the immunobiology of liver transplant 
rejection is still incomplete. Various findings suggest that 
the ilTlJ1unologic course of 1 iver transplants differs 
sub s tan t i a I 1 Y from t hat 0 f 0 the r sol i d 0 r g ant ran s p I ant s 
(1-8). T-Iymphocytes are known to playa major role in cell 
mediated allograft rejection (9-10). In cellular infiltrates 
of transplants it is possible to demonstrate activated T 
cells expressing Interleukin-2 (lL-2) receptors on their 
cell surface. These cells are capable of undergoing further 
proliferation upon exposure to IL-2 (11-12). 
Previous studies have shown that activated T-cells can 
be propagated in vitro from liver allograft biopsies in the 
presence of exogenous recombinant IL-2 (13,14). Further 
analysis of these biopsy grown lymphocytes h,s revealed the 
presence of alloreactive T-cells specific for donor HLA 
antigens. Often enough, these cell cultures exhibit 
restricted specificity patterns against one or few of the 
donor HLA antigens. This alloreactivity could also be 
blocked with monoclonal antibodies (moAb) against 
appropriate HLA determinants. Similar observations have been 
made wi th lymphocyte cuI tures grown from heart transplant 
biopsies (15). In certain patients, there appeared a 
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sequential infiltration of the allograft by class I specific 
lymphocytes in earlier biopsies followed by class II or 
mixed class 1/11 specific lymphocytes in later biopsies 
( 16) • 
Th e aim 0 f t his stu d Y was toe val u ate the ass 0 cia ti 0 n 
of the HLA class I and class II allospecificity of 
lymphocytes grown from liver allograft biopsies with 
clinical, biochemical and histopathologic findings. 
MATERIALS AND ME'IBODS 
All liver transplant recipients received cyclosporine 
and steroids as immunosuppressive drugs. As of December 1984 
OKT3 monoc 1 onal an t i body the r apy has been added tot r ea t 
acute rejection episodes. Samples of hepatic allografts were 
obtained from percutaneous 1 iver biops ies or removed 
allografts. Indications for sampling were derangements in 
1 i ve r fun c t ion t est san d b i 1 e c omp 0 sit ion • ~t i simp 0 r tan t 
to emphasize, 
occurred and 
that all biopsies were obtained when problems 
that these were no protocol biopsies. All 
samples were taken in a sterile manner for propagation of 
infiltrating cells and histologic evaluation. No attempt for 
HLA matching of liver transplants was made, because of the 
very limited time available for all the events related to 
the harvesting and transplant procedure. 
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Liver biopsies were divided into smaller segments and 
cultured in microculture wells with 100 ul of recombinant 
IL-2 and 100 ul of tissue culture medium as described 
pre v i 0 u sly ( 13 ). Th e cui t u res we reo b s e r v e d d a i I yon an 
inverted stage microscope and supplemented with IL-2 at 2-3 
day intervals. After approximately 2 weeks, sufficient cells 
(0.5-1.0xl0 6 ) were obtained for primed lymphocyte testing 
(PLT) assays. The cuI tured lymphocytes were tested against 
cryopreserved donor splenocytes, exogenous IL-2 and an 
informative panel of unrelated lymphocytes with known HLA 
type. In blocking studies different anti-class I and anti-
class II moAb were tested for their inhibitory effect on the 
PLT response of these cultured T cells. One or more of the 
following moAb, with their corresponding HLA molecular 
specificity, were selected: SG157 (anti-DR) and SG465 (broad 
anti-class II) (S. Goyert and J.Silver [17]); L243 (anti-DR) 
and Leu 10 (anti-DQwl + w3)(Becton Dickinson, Mountain View, 
CA [18-20]); PA2.6 (anti-HLA-A,B,C)(P.Parham[21,22]); or 
w6/32 (anti HLA - A, B, C)(Pel-Freez, Rogers_ Arkansas [23-
24]) • 
Information about the clinical and biochemical data 
prior to taking a biopsy was obtained from a review of the 
medical charts with special attention to the time interval 
after the liver transplant procedure, total and direct 
bilirubin (T-BIL, D-BIL), serum glutamate oxaloacetic 
transaminase (SOOT), serum glutamate pyruvate transaminase 
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(SGPT), alkaline phosphatase (AP) and gamma glutamyl 
transpeptidase (GGTP). All values were recorded from the day 
before obtaining the biopsies. 
All liver tissue submitted for histopathologic review 
was taken from the same biopsy core or from the same region 
of the liver (in failed allografts) as samples utilized for 
lymphocyte cultures. The tissues were fixed in neutral 
buffered formalin, sectioned at 6 microns and routinely 
stained with hematoxylin, eosin, and trichrome stains. 
Histologic sections were examined in a blind manner by one 
of us (A.J.D.). Each biopsy specimen was reviewed according 
to a defined protocol developed for the National Liver 
Transplant Data Base (25). This protocol histopathologic 
examination includes thirty criteria with special emphasis 
on findings considered to be important in hepatic rejection, 
namely the presence of a mononuclear portal inflammatory 
infiltrate associated with ductal epithelial and venular 
endothelial damage (26). _ 
Statistical analysis of relevant data was performed by 
the nonparametric statistical tests of Mann-Whitney and 
Kruskal-Wallis using the SPSSPC software package (27). 
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RESULTS 
For 35 out of 67 lymphocyte cuI tures establ ished from 
liver allograft biopsies we could assess a specificity 
towards HLA class I (n=8), mixed HLA class I and I I (n=15) 
or HLA class II antigens (n=12). Clinicopathologic data 
including biochemical parameters and histopathological 
findings are shown in Table 1. It may be seen, that there 
was considerable heterogeneity in the laboratory values of 
the total population and often enough in the various 
subgroups of transplant recipients. Nevertheless, this 
database proved useful in analyzin~ differences between 
biopsies yielding class I versus class II specific T cells 
after in vitro propagation and expansion. 
It was noted, that class I specific cells were 
g e n era ted from b i 0 psi e sob t a i ned ear lie r d uri n g the po s t -
transplant period than those yielding class II specific 
cells. The median post transplant periods ... were 8.5 days 
(range from 4 to 48) for HLA class I, 17 days (range from 2 
to 237) for HLA class 1/11 and 29 days (range from 5 to 753) 
for HLA class II specific T-cell cultures (class I vs. class 
II, p=O.003) (Table 2). 
No statistically significant differences were found in 
the bilirubin, SOOT and SGPT values for the different 
groups, although a trend towards higher values for biopsies 
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exhibiting class II specific T-cells was noted (Table 2). 
However we observed statistically significant elevations of 
GGTP and AP values associated with HLA class II specific 
cells in the biopsy derived lymphocyte cultures (class I vs 
class II: for GGTP p=0.017, for AP p=O.014) (Table 2). A 
trend versus higher values of bile duct damage was noted in 
biopsies yielding class II specific lymphocyte cultures. 
This elevation was statistically significant when the both 
biopsies presenting only with harvesting injury were 
excluded from the analysis (p=O.038). 
Histopathologic exa~ination showed that 5 of 8 biopsy 
specimens yielding class I HLA specific lymphocytes, had 
undergone mild to severe portal tract inflarrmation. The 
cellular infiltrate consisted of an admixture of cells 
typical of that described for acute cellular rejection (26). 
Two patients in the class I specific group showed 
histological signs of recurrent hepatitis. The pretransplant 
diagnosis of patient 942 was chronic liver Jailure due to 
non A, non B hepatitis and patient 914 originally had 
endstage liver disease due to chronic active hepatitis B. 
The percentage of damaged bil iary ducts was in all cases 
equal to or less than 6096. 
Biopsies from specimens with HLA class II specificity 
only, generally showed mild to moderate portal tract 
infiltration. In no instance was the portal inflammation 
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scored as "severe". Two biopsies (patients no. 499, biopsy 
from day 5; 6 4 7, b i 0 p s y from day 6 ) i nth e cIa s s I Ion 1 y 
group were 
Both were 
obtained during the first week post transplant. 
diagnosed as harvesting injury. Based on the 
histologic evaluation, rejection was not thought to be the 
cause of graft dysfunction in these two instances, although 
biopsy grown lymphocytes showed donor specific 
alloreactivity. 
The remaining allograft biopsy specimens yielding class 
II only specific lymphocytes showed a mild (n=5) or moderate 
(n=5) port~l infiltrate. In these ten biopsies, the percent 
of bile duct damage in patients with primary rejection was 
higher than in both other groups. These and subsequent 
b i 0 P s Y s am pie s from f 0 u r p a ti en t 5 ( P a ti en t s no. 3 39 , 3 46 , 
353, 472) showed indolent, ongoing chronic rejection with 
prominent duct damage. Three of these grafts were later lost 
because of a paucity of bile ducts and obliterative 
vasculopathy. 
Biopsies yielding both HLA class I and II reactive 
lymphocytes displayed histopathologic findings intermittent 
between the two groups. The diagnoses varied from 
preservation injury to severe rejection. Notably, one of the 
patients with both class I and II donor specific reactivity 
(patient no. 673) experienced progressive graft dysfunction 
resulting in later graft loss from chronic rejection. 
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In four patients two biopsies were taken from the same 
graft at various times post transplant (patients no. 673 
first graft, 673 second graft, 490, 493). In three of these 
cases serial biopsies showed the same specificity for the 
infiltrates. In one case (patient no. 490) the first biopsy 
showed a class I specific infiltrate and a biopsy performed 
four days later showed a mixed class I and II specific 
infiltrate. For patient 673 both biopsies of the first liver 
allograft rendered a class I specific infiltrate, while 
biopsies of the retransplant showed very early a mixed class 
I and II specific infiltrate. 
DISaJSSI<Jf 
Immunocytochemical analysis has previously shown a 
selective destruction of bile ducts in liver allografts 
undergoing rejection as demonstrated by striking elevations 
of GG1P activity (28). It has been postulated that the 
induced expression of DR antigens on structuris targeted for 
immune destruction may be an important event in the 
pathogenesis of liver allograft rejection. The current 
analysis suggests that the increased destruction 
duct epithelium might be associated with HLA 
specific lymphocytes invading the allograft tissue 
of bile 
class II 
and that 
this damage might be selectively restricted to HLA class II 
bearing target structures, namely the biliary epithelium. In 
our analysis infiltration with class II specific cells was 
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associated with a statistically significant elevation of 
mean GGTP, AP, and a higher degree of bile duct damage. GGTP 
is specifically released at times of biliary epithelial cell 
(BEC) damage. In addition BEC are the main structural 
element being capabte of expressing HLA class II antigens in 
the liver allograft and are a preferential target for 
invading lymphocytes (28). These events might not be easily 
revealed at histologic examination, since reports from heart 
biopsies presenting with a histological grade 0 according to 
Billingham (no lymphocytic infiltrate) have shown, that 
still from about 30% of these biopsies activated lymphocyte 
cultures can be established (29). 
Even at later days post-transplant two biopsy specimens 
presented with a class I infiltrate (patients no. 914, 942). 
Both rendered a histological primary diagnosis of recurrent 
hepatitis. Hepatocytes are believed to express mainly class 
I ant i g ens ( 30 , 3 1 s u bm itt e d ) and vir a lin f e c t ion s , 
restricted to hepatocytes are shown to in~rease class I 
ant i g e n ex pre s s ion (3 2 ). Th ism i g h t ex p I a ina n ass 0 cia t ion 
of class I specific T cell infiltrates with infectious 
process in the liver allograft restricted to hepatocytes. 
Previous studies have shown that biopsy grown 
lymphocytes from certain heart allografts exhibited a trend 
towards HLA class I specific cells being more predominant in 
earlier biopsies, followed by mixed HLA class 1/11 or class 
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11 specific cells in later biopsies (16). The same trend was 
noted here in lymphocytes grown from liver allografts. Class 
I specific lymphocytes might playa role in inducing the 
primary steps of the rejection cascade. On vascular 
endothelial cells class I antigens rather than class II are 
present early after transplantation. These class I antigens 
can serve as specific recognition structures, thereby 
facilitating the preferential adherence of class I specific 
I ymphocy t es to vascu I ar endo t he 1 i urn and the i r subsequen t 
migration into the surrounding tissues (29, 33 submitted). 
Through the release of lymphokines, specifically gamma-
Interferon (Y-IFN), these invading class I specific 
lymphocytes can promote additional HLA class II antigen 
expression on the vascular endothelial cells (34 submitted) 
wit h sub seq u e n t c I ass I I s p e c i f i c I ymp hoc Y tea d her en c e and 
invasion (33 submitted). These class II specific lymphocytes 
might then recognize class I I ant igens on BEC, leading to 
subsequent BEC damage as shown by elevated ~rum levels of 
GGTP and AP. 
In addition, various other factors such as ischemia and 
viral infections might serve as class II antigen promotors 
on vascular endothelial cells and BEC, thereby facilitating 
class II specific infiltrates and promoting class II 
specific intragraft effector mechanisms. Interestingly, 
harvesting injury was determined to be the major cause of 
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liver dysfunction In both cases in which biopsies were taken 
during the first week after transplantation and the 
subsequent lymphocyte culture displayed HLA class II 
specificity. 
The limited experience does not allow firm conclusions, 
but it seems interesting to note, that class I specific 
i nf i I tra tes even when showi ng more severe signs of acu te 
rejection were associated with a favorable response to the 
currently used rejection treatment with OKT3, steroids, 
adjustment of cyclosporine and in some cases additional 
Imuran. On the other hand biopsies from 4 allografts sh~wed 
at histologic examination chronic rejection with a very high 
degree of bile duct loss. All these specimens rendered a 
class II specific infiltrate. There was no biopsy showing 
chronic rejection in the class I or the mixed class Illl 
specific groups. 
The histopathologic findings described ~n this report 
although limited in number, offer some interesting avenues 
for further investigation. However, more evaluation is 
needed in terms of defining the type of donor specificity 
(I.e. proliferative vs cytotoxic response), examining any 
lymphocyte activity against viral or autoirrmune antigens, 
the addition of greater numbers to confirm these 
observations, and the sequential culturing of samples from 
the same patient. 
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Table 2: Analysis of clinicopathologic data 
ass 0 cia ted t 0 HLA s p e c i f i cit Y 0 f I i ve r 
allograft infiltrating lymphocytes 
---...... --- ---.--- ---- --------.----.---------.----- -- ----.-....--------------------.------.------------------------------------..--
CLASS BIOP-
SIES 
DAYS 
TO 
LTX 
BILIRUBIN SGPT 
D T 
mg/dl mg/dl U/ml 
MEDIAN 
(RANGE) 
SOOT 
U/ml 
GGTP 
IU/ml 
AP BILE DUCT 
LOSS 
IU/ml 
-----.--------------.-.--- ----------------.- ------------.----------;---------.-----------------------------------------
I 
I I II 
II 
8 
15 
12 
8.5 
(4-
48) 
17.0 
(2-
237) 
29.0 
(5-
753) 
4.3 
(1. 6-
10.0) 
5.2 
(0.2-
27.6) 
6.4 
( 1.1-
14.0) 
6.7 
(2.2-
14.9) 
8.4 
(0.9-
47.5) 
10.2 
(1. 7-
22.6) 
46.0 
(6-
1472) 
58.0 
(11-
2252) 
200.0 
(26-
5449) 
65.0 
( 4-
673) 
54.0 
(11-
978) 
126.5 
( 28-
3228) 
142.0 
(92-
397) 
178.0 
( 47-
2936) 
36i·O 
(94-
1031) 
170.0 
( 18-
277) 
262.0 
(64-
1563) 
332.0 
(100-
516) 
25.0 
( 0-
60) 
40.0 
( 0-
90) 
55.0 
( 0-
90) 
P-values for class I vs. class II: 
• 
all biopsies: 
0.076 0.440 0.487 0.203 0.142 0.017* 0.014* 0.212 
only biopsies with histologic evidence of rejection: * 
0.003 0.806 0.806 0.902 0.540 0.005 0.010· 0.038+* 
statistically significant 
+ only two biopsies showing harvesting injury were excluded from the analysis 
